MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway
MYO6 has pro-tumor and Enz-resistant effects in CRPC, suggesting that targeting MYO6 may be beneficial for ENZ-resistant CRPC therapy through the AR/MYO6/FAK signaling pathway.
Authors
- Tao Feng (ORCID: https://orcid.org/0000-0001-6835-0275)
- Zhe Hong (ORCID: https://orcid.org/0000-0001-5942-4893)
- Shengfeng Zheng
- Junhong Li (ORCID: https://orcid.org/0000-0001-5722-197X)
- Zi-Hao Zhang (ORCID: https://orcid.org/0009-0001-0191-1725)
- Yao Tan (ORCID: https://orcid.org/0000-0002-8397-5721)
- Dingwei Ye (ORCID: https://orcid.org/0000-0003-4974-3780)
- Guowen Lin
- Zongyuan Hong
- Yue Wang (ORCID: https://orcid.org/0000-0002-3241-6356)
Institutions
- Wannan Medical College (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Cancer Institute (CN)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1186/s12964-024-01897-z
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- National Natural Science Foundation of China